Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?

• Luxiang Wang,
• Chunli Zhang,
• Shuang Fan,
• Xiaodong Mo,
• Xiaoxia Hu

Affiliations

Luxiang Wang

Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China; Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Chunli Zhang

Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Shuang Fan

Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China

Xiaodong Mo

Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China; Corresponding author

Xiaoxia Hu

Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China; Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Corresponding author